- Home
- SF vs ARWR Comparison
SF vs ARWR Comparison
Compare SF & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SF | ARWR |
|---|---|---|
| Founded | 1890 | 2003 |
| Country | United States | United States |
| Employees | 9000 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.2B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | SF | ARWR |
|---|---|---|
| Price | $73.54 | $81.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $90.33 | $83.40 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $14.58 | N/A |
| Revenue Next Year | $8.03 | N/A |
| P/E Ratio | $20.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $67.96 | $14.30 |
| 52 Week High | $134.74 | $84.55 |
Technical Indicators
Market Signals| Indicator | SF | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 62.31 |
| Support Level | $68.63 | $70.05 |
| Resistance Level | $74.07 | $82.26 |
| Average True Range (ATR) | 1.63 | 4.14 |
| MACD | 0.62 | 0.60 |
| Stochastic Oscillator | 76.18 | 82.11 |
Price Performance
Historical ComparisonAbout SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.